Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Preventing Chemotherapy-induced Hair Loss?
Preventing Chemotherapy-induced Hair Loss?
Preventing chemotherapy-induced hair loss would be important for many newly diagnosed myeloma patients (NDMM). According to research,
- chemotherapy-induced hair loss is experienced by 65% of cancer patients.
- 47% of female cancer patients consider it the most traumatic aspect of their treatment*.
ChatGPT said:
Therapies shown to prevent or reduce chemotherapy-induced alopecia (CIA) fall into two main categories: scalp cooling technologies and experimental or pharmacologic interventions. Here’s a summary of the evidence:
✅ Proven or Clinically Used Interventions
1. Scalp Cooling (Cold Caps and Scalp Cooling Systems)
-
Mechanism: Vasoconstriction reduces blood flow (and chemotherapy delivery) to hair follicles.
-
Devices: FDA-cleared systems include:
-
DigniCap
-
Paxman Scalp Cooling System
-
-
Evidence:
-
Multiple RCTs and meta-analyses confirm effectiveness, especially with taxane-based regimens (e.g., docetaxel, paclitaxel).
-
Success rates vary: 50–70% hair retention with cold caps.
-
-
Limitations:
-
Less effective with anthracyclines (e.g., doxorubicin).
-
Not suitable for hematologic malignancies due to theoretical risk of scalp metastases.
-
Can cause cold-related discomfort.
-
🧪 Investigational or Emerging Therapies
2. Topical Minoxidil (Rogaine)
-
Use: Often considered for post-chemo regrowth, but limited benefit for preventing CIA.
-
Studies: Mixed results; may shorten duration of alopecia but doesn’t significantly prevent it during treatment.
3. Keratinocyte Growth Factors (e.g., Palifermin)
-
Mechanism: Stimulates epithelial cell growth.
-
Evidence: Some protective effect in animal models and small trials, but not approved for CIA prevention.
4. CDK4/6 Inhibitors
-
Mechanism: May protect hair follicles by halting their cycling during chemotherapy.
-
Status: Preclinical stage or early-phase studies.
5. Antioxidants and Natural Compounds
-
Agents such as tocotrienols, curcumin, and N-acetylcysteine have been studied for their protective effects in cell and animal models.
-
Status: No strong human trial data to recommend.
🛑 Ineffective or Not Recommended
-
Wigs and scalp prostheses: Used for cosmetic support but do not prevent CIA.
-
Steroids, Vitamin E, Biotin, or other supplements: No proven efficacy in preventing CIA.
Summary Table
| Therapy | Evidence Strength | Key Notes |
|---|---|---|
| Scalp Cooling Devices | Strong | FDA-cleared, most effective for taxanes |
| Minoxidil (Topical) | Weak/Moderate | May aid regrowth, not prevention |
| Palifermin (KGF) | Experimental | Promising in animals, not for routine use |
| CDK4/6 Inhibitors | Preclinical | Hypothetical benefit, under research |
| Natural Antioxidants | Preclinical | No clinical proof |
When I was diagnosed with multiple myeloma, all my hair fell out about halfway through my induction therapy. To be honest, my hair had been slowly falling out ever since I began my induction therapy.
I wasn’t too distressed when it happened. Maybe because I was expecting my hair to fall out. Maybe because baldness runs in my family. Maybe because Michael Jordan was in the news.
If you are an NDMM patient and you think that preventing chemotherapy-induced hair loss is important to you, this post may be useful to you.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about managing your MM with both conventional and non-conventional therapies.
Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
New Breakthrough In Preventing Chemotherapy-Induced Hair Loss
Groundbreaking new research has revealed a promising and novel method to aid the scalp cooling process in the prevention of hair loss in cancer patients undergoing chemotherapy offering hope to hundreds of thousands of people around the world affected by the distressing side effect of treatment every year.
Researchers in the University’s Biomolecular Sciences Research Centre, at Sheffield Hallam University, in partnership with Paxman, have discovered that combining scalp cooling treatment with antioxidants can significantly reduce or even prevent the damage to hair follicles caused by chemotherapy drugs. This breakthrough has the potential to enhance and standardise scalp cooling efficacy levels, potentially transforming it into a more consistent and universally reliable method…
The paper, which has been published today in the journal Frontiers of Pharmacology, showed for the first time that:
- Cooling of human hair follicles to an optimal temperature of 18°C prevents chemotherapy-induced hair follicle damage.
- Sub-optimal cooling at 26°C provides inadequate protection from chemotherapy which may explain why, for some patients, scalp cooling is not effective.
- When combined with antioxidants, such as N-Acetylcysteine or Resveratrol, even sub-optimal cooling temperatures provided substantial protection, comparable to optimal cooling.
- The combined approach effectively reduces the levels of reactive oxygen species (ROS), harmful molecules produced during chemotherapy that contribute to hair follicle damage.
- The combination (cooling with antioxidant) compensates for inefficient sub-optimal cooling and provides a powerful combination that can transform the clinical efficacy of scalp cooling.
Dr Nik Georgopoulos, Associate Professor in Cell Biology and Transforming Lives Fellow at Sheffield Hallam University, said: “Our findings suggest that the combination of cooling and antioxidants could be a game-changer in preventing chemotherapy-induced hair loss and could make a real difference to the lives of cancer patients worldwide…
Approximately 65% of people undergoing chemotherapy experience hair loss. It is one of the most feared side effects of chemotherapy, with 47% of female cancer patients considering it the most traumatic aspect of their treatment*.
This innovative approach could enhance the effectiveness of existing scalp cooling treatments, offering a new hope for cancer patients who experience distressing hair loss during chemotherapy…
“Losing my hair was one of the most devastating parts of going through treatment – losing hair every time I showered was traumatising and there were times I wanted to give up [scalp cooling], but I am SO thankful I didn’t.” – Robyn
Through nearly 15 years of research, Dr Georgopoulos’ team has shown that by reducing the temperature of the scalp before, during, and after chemotherapy treatment, scalp cooling triggers multiple beneficial biological effects that help protect hair follicles from the toxic effects of chemotherapy drugs. Cooling causes blood vessel narrowing to preserve heat, which reduces blood flow to as little as 20%, meaning less chemotherapy drug reaches the hair follicles. Cooling also directly prevents the entry of chemotherapy drugs into cells. In addition, scalp cooling causes hair cells to become dormant and stop dividing so that the chemotherapy treatment, which targets rapidly dividing cells, will bypass them. To add to this knowledge, this new publication proves that cooling reduces cellular metabolism and toxic ROS production. Thus, optimal scalp cooling can protect from hair loss because of its ability to trigger all these protective mechanisms at the same time.
Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?
Abstract
Millions of new cancer patients receive chemotherapy each year. In addition to killing cancer cells, chemotherapy is likely to damage rapidly proliferating healthy cells, including the hair follicle keratinocytes. Chemotherapy causes substantial thinning or loss of hair, termed chemotherapy-induced alopecia (CIA), in approximately 65% of patients. CIA is often ranked as one of the most distressing adverse effects of chemotherapy, but interventional options have been limited.
To date, only scalp cooling has been cleared by the US Food and Drug Administration (FDA) to prevent CIA. However, several factors, including the high costs not always covered by insurance, preclude its broader use.
Here we review the current options for CIA prevention and treatment and discuss new approaches being tested. CIA interventions include
- scalp cooling systems (both non-portable and portable)
- and topical agents to prevent hair loss,
- versus topical and oral minoxidil,
- photobiomodulation therapy (PBMT),
- and platelet-rich plasma (PRP) injections,
among others, to stimulate hair regrowth after hair loss…”